A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children (WORMCON)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01087099 |
Recruitment Status :
Completed
First Posted : March 15, 2010
Last Update Posted : August 2, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Infections With Soil-Transmitted Helminths (STH) | Drug: Albendazole | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1750 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children |
Study Start Date : | January 2009 |
Actual Primary Completion Date : | December 2009 |
Actual Study Completion Date : | March 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: Albendazole
Treatment with albendazole
|
Drug: Albendazole
Treatment with albendazole |
- Efficacy of albendazole [ Time Frame: 14 to 30 days after treatment ]To determine the efficacy of albendazole, and this will be assessed by the reduction in parasite faecal egg counts between the pre- and post-intervention surveys. The latter will be conducted 14-30 days after treatment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years to 14 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children should be infected with a minimum of 150 eggs/gram of any of the three species of STH (i.e. Ascaris or hookworms or Trichuris).
Exclusion Criteria:
- Not willing to participate
- Unable to give samples for follow up
- Severe intercurrent medical condition
- Diarrhoea at first sampling

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01087099
Brazil | |
Instituto René Rachou, Fundação Oswaldo Cruz | |
Minas Gerais, Brazil | |
Cambodia | |
Institut Pasteur in Cambodia, Clinical Pathology Unit | |
Phnom Penh, Cambodia | |
Cameroon | |
Centre for Schistosomiasis and Parasitology, Faculty of Sciences, University of Yaoundé I | |
Yaounde, Cameroon | |
Ethiopia | |
Department of Medical Laboratory Sciences and Pathology , College of Public Health and Medical Sciences, Jimma University | |
Jimma,, Ethiopia | |
India | |
Department of Gastrointestinal Sciences, Christian Medical College | |
Vellore, India | |
Tanzania | |
Public Health Laboratory | |
Zanzibar, Tanzania | |
Vietnam | |
National Institute for Malariology, Parasitology and Entomology | |
Hanoi, Vietnam |
Principal Investigator: | Jozef Vercruysse | University Ghent |
Responsible Party: | Jozef Vercruysse, University Ghent |
ClinicalTrials.gov Identifier: | NCT01087099 |
Other Study ID Numbers: |
2008/322 |
First Posted: | March 15, 2010 Key Record Dates |
Last Update Posted: | August 2, 2011 |
Last Verified: | July 2011 |
Infection Communicable Diseases Nematode Infections Helminthiasis Parasitic Diseases Albendazole Anthelmintics Antiparasitic Agents Anti-Infective Agents |
Anticestodal Agents Antiplatyhelmintic Agents Antiprotozoal Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |